Hims and Hers vs. Teladoc
NASDUCK Duel
This week, we're diving into the booming world of telehealth, pitting two major players against each other: Hims & Hers Health (HIMS) versus the veteran Teladoc Health (TDOC). For an audio podcast summary, scroll down to the Members section below.
🥊 This Week's Contenders
First up is Hims & Hers ( HIMS 0.00%↑ ). You've probably seen their ads. They started in 2017, focusing direct-to-consumer for things like hair loss and sexual health, first for men (Hims), then women (Hers). They've grown like a weed, adding mental health and, more recently, jumping into the popular weight-loss drug market. They went public via a SPAC in 2021 and their stock has been on a tear lately, fueled by that rapid expansion and impressive revenue growth – hitting $1.5 billion in 2024, up a whopping 69%.
Then we have Teladoc ( TDOC 0.00%↑ ). These guys are pioneers, founded way back in 2002. They're a much bigger, more established operation, working with employers and health plans, offering everything from urgent care calls to chronic condition management (thanks to buying Livongo) and mental health (especially through BetterHelp). They reach over 90 million Americans and operate globally. But lately? It's been rough. Their stock has taken a beating, revenue growth has slowed (even dipped slightly last quarter), and their big BetterHelp division is shrinking. They're trying to turn things around with new leadership, acquisitions like UpLift for mental health, and focusing on AI and partnerships, like one with Lilly for branded weight-loss drugs.
So, we have the relatively young, fast-growing disruptor versus the established giant trying to find its footing again. Let's see how they stack up head-to-head based on the numbers.
📊 The Duel
We break this down across different time horizons to get a full picture.